{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T02:34:52Z","timestamp":1794105292127,"version":"4.8.0"},"reference-count":74,"publisher":"Societatea Romana de Morfologie","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rom J Morphol Embryol"],"published-print":{"date-parts":[[2025,8,27]]},"abstract":"<jats:p>Introduction: Cardiac amyloidosis (CA) represents a progressively evolving infiltrative pathology, defined by the myocardial accumulation of amyloid fibrils. The condition predominantly originates from transthyretin-derived (ATTR) or immunoglobulin light chain-related (AL) amyloidosis. ATTR cardiomyopathy (ATTR-CM), particularly the wild-type (wt) form (wtATTR-CM), is becoming more widely acknowledged as a contributor to cardiac dysfunction in the elderly population. However, diagnosing ATTR-CM remains challenging due to its clinical similarity to other cardiac conditions and a history of frequent misdiagnoses. Recent advancements in nuclear imaging using bone-avid radiotracers have greatly improved the ability to diagnose ATTR-CM non-invasively. Case presentation: This case involves an 86-year-old male with documented peripheral joint disease, supraspinatus tendon rupture affecting both limbs, referred for exertional dyspnea. Echocardiography indicated left ventricular hypertrophy, diastolic dysfunction, reduced global longitudinal strain, accompanied by severe mitral regurgitation (MR) secondary to prolapse of the posterior mitral leaflet. Cardiac magnetic resonance (CMR) imaging revealed concentric hypertrophy, elevated T1 mapping, and increased extracellular volume, highly suggestive of amyloid deposition. Bone scintigraphy confirmed the diagnosis of ATTR-CM with a Perugini score of 3. A biopsy of the abdominal fat pad revealed amyloid deposits. Conclusions: Such presentations of ATTR-CM emphasize its systemic nature and the need for early recognition and treatment. An important aspect of this case is the uncommon association between CA and posterior mitral valve prolapse, which leads to significant MR.<\/jats:p>","DOI":"10.47162\/rjme.66.2.02","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T12:31:18Z","timestamp":1756729878000},"page":"279-289","source":"Crossref","is-referenced-by-count":1,"title":["Wild-type transthyretin cardiac amyloidosis: a case of multisystemic involvement and review of literature"],"prefix":"10.47162","volume":"66","author":[{"name":"Department of Physiology, University of Medicine and Pharmacy of Craiova, Romania; Emergency County Clinical Hospital, Craiova, Romania","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana Gianina","family":"Moise","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Elena","family":"Negroiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Pathophysiology, University of Medicine and Pharmacy of Craiova, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana","family":"Mirea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Emergency County Clinical Hospital, Craiova, Romania; Department of Cardiology, University of Medicine and Pharmacy of Craiova, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robertina Iulia","family":"Tudora\u015fcu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Pathophysiology, University of Medicine and Pharmacy of Craiova, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia Georgiana","family":"V\u00eenturi\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Pathophysiology, University of Medicine and Pharmacy of Craiova, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzana","family":"D\u0103noiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Pathophysiology, University of Medicine and Pharmacy of Craiova, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ionu\u0163","family":"Donoiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Emergency County Clinical Hospital, Craiova, Romania; Department of Cardiology, University of Medicine and Pharmacy of Craiova, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea","family":"\u015etefan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Emergency County Clinical Hospital, Craiova, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Cornel","family":"Raicea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Emergency County Clinical Hospital, Craiova, Romania; Department of Cardiovascular Surgery, University of Medicine and Pharmacy of Craiova, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26736","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"\"[1] Garcia Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, Burazor I, Caforio ALP, Damy T, Eriksson U, Fontana M, Gillmore JD, Gonzalez-Lopez E, Grogan M, Heymans S, Imazio M, Kindermann I, Kristen AV, Maurer MS, Merlini G, Pantazis A, Pankuweit S, Rigopoulos AG, Linhart A. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J, 2021, 42(16):1554-1568. https:\/\/doi.org\/10.1093\/eurheartj\/ehab072","DOI":"10.1093\/eurheartj\/ehab072"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"[2] Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation, 2017, 135(14):1357-1377. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.024438","DOI":"10.1161\/CIRCULATIONAHA.116.024438"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"[3] Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet, 2016, 387(10038):2641-2654. https:\/\/doi.org\/10.1016\/S0140-6736(15)01274-X","DOI":"10.1016\/S0140-6736(15)01274-X"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"[4] Gorrie N, Geenty P, Rye E, Sivasubramaniam V, Carroll A, McCaughan G, Thomas L, Fatkin D, Bart N. Atrial cardiomyopathy in cardiac amyloidosis: clinical imaging and manifestations. npj Cardiovasc Health, 2025, 2(1):8. https:\/\/doi.org\/10.1038\/s44325-025-00043-z","DOI":"10.1038\/s44325-025-00043-z"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"[5] Griffin JM, Rosenthal JL, Grodin JL, Maurer MS, Grogan M, Cheng RK. ATTR amyloidosis: current and emerging management strategies: JACC: CardioOncology state-of-the-art review. JACC CardioOncol, 2021, 3(4):488-505. https:\/\/doi.org\/10.1016\/j.jaccao.2021.06.006","DOI":"10.1016\/j.jaccao.2021.06.006"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"[6] Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol, 2019, 73(22):2872-2891. https:\/\/doi.org\/10.1016\/j.jacc.2019.04.003","DOI":"10.1016\/j.jacc.2019.04.003"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"[7] Kelly JW, Colon W, Lai Z, Lashuel HA, McCulloch J, McCutchen SL, Miroy GJ, Peterson SA. Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid. Adv Protein Chem, 1997, 50:161-181. https:\/\/doi.org\/10.1016\/S0065-3233(08)60321-6","DOI":"10.1016\/S0065-3233(08)60321-6"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"[8] Gonzalez Lopez E, McPhail ED, Salas Anton C, Dominguez F, Gertz MA, Dispenzieri A, Dasari S, Milani P, Verga L, Grogan M, Palladini G, Garcia-Pavia P. Histological typing in patients with cardiac amyloidosis: JACC review topic of the week. J Am Coll Cardiol, 2024, 83(11):1085-1099. https:\/\/doi.org\/10.1016\/j.jacc.2024.01.010","DOI":"10.1016\/j.jacc.2024.01.010"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"[9] De Michieli L, De Gaspari M, Sinigiani G, Lupi A, Vedovelli L, Salvalaggio A, Della Barbera M, Rizzo S, Pilichou K, Cecchin D, Briani C, Gregori D, Tarantini G, Berno T, Trentin L, Basso C, Corrado D, Iliceto S, Perazzolo Marra M, Cipriani A. Chest pain in cardiac amyloidosis: occurrence, causes and prognostic significance. Int J Cardiol, 2023, 389:131204. https:\/\/doi.org\/10.1016\/j.ijcard.2023.131204","DOI":"10.1016\/j.ijcard.2023.131204"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"[10] Dorbala S, Vangala D, Bruyere J Jr, Quarta C, Kruger J, Padera R, Foster C, Hanley M, Di Carli MF, Falk R. Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Fail, 2014, 2(4):358-367. https:\/\/doi.org\/10.1016\/j.jchf.2014.03.009","DOI":"10.1016\/j.jchf.2014.03.009"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"[11] Connors LH, Sam F, Skinner M, Salinaro F, Sun F, Ruberg FL, Berk JL, Seldin DC. Heart failure resulting from age related cardiac amyloid disease associated with wild type transthyretin: a prospective, observational cohort study. Circulation, 2016, 133(3):282-290. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.018852","DOI":"10.1161\/CIRCULATIONAHA.115.018852"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"[12] Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, Singleton A, Kiuru-Enari S, Paetau A, Tienari PJ, Myllykangas L. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population based autopsy study. Ann Med, 2008, 40(3):232-239. https:\/\/doi.org\/10.1080\/07853890701842988","DOI":"10.1080\/07853890701842988"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"[13] Cornwell GG 3rd, Murdoch WL, Kyle RA, Westermark P, Pitk\u00e4nen P. Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med, 1983, 75(4):618-623. https:\/\/doi.org\/10.1016\/0002-9343(83)90443-6","DOI":"10.1016\/0002-9343(83)90443-6"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"[14] De Michieli L, Stoppa G, Sinigiani G, Previato L, Lorenzoni G, Salvalaggio A, Berno T, Perazzolo Marra M, Briani C, Iliceto S, Biggeri A, Catelan D, Cipriani A. Hospitalization-based epidemiology of systemic and cardiac amyloidosis in the Veneto Region, Italy. Int J Cardiol, 2024, 400:131804. https:\/\/doi.org\/10.1016\/j.ijcard.2024.131804","DOI":"10.1016\/j.ijcard.2024.131804"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"[15] Gonz\u00e1lez-L\u00f3pez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, Alonso-Pulpon L, Garcia-Pavia P. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J, 2015, 36(38):2585-2594. https:\/\/doi.org\/10.1093\/eurheartj\/ehv338","DOI":"10.1093\/eurheartj\/ehv338"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"[16] Brito D, Albrecht FC, de Arenaza DP, Bart N, Better N, Carvajal-Juarez I, Concei\u00e7\u00e3o I, Damy T, Dorbala S, Fidalgo JC, Garcia-Pavia P, Ge J, Gillmore JD, Grzybowski J, Obici L, Pi\u00f1ero D, Rapezzi C, Ueda M, Pinto FJ. World Heart Federation Consensus on transthyretin amyloidosis cardiomyopathy (ATTR-CM). Glob Heart, 2023, 18(1):59. https:\/\/doi.org\/10.5334\/gh.1262","DOI":"10.5334\/gh.1262"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"[17] Geller HI, Singh A, Alexander KM, Mirto TM, Falk RH. Association between ruptured distal biceps tendon and wild-type transthyretin cardiac amyloidosis. JAMA, 2017, 318(10):962-963. https:\/\/doi.org\/10.1001\/jama.2017.9236","DOI":"10.1001\/jama.2017.9236"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"[18] Sueyoshi T, Ueda M, Jono H, Irie H, Sei A, Ide J, Ando Y, Mizuta H. Wild-type transthyretin-derived amyloidosis in various ligaments and tendons. Hum Pathol, 2011, 42(9):1259-1264. https:\/\/doi.org\/10.1016\/j.humpath.2010.11.017","DOI":"10.1016\/j.humpath.2010.11.017"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"[19] Irabor B, McMillan JM, Fine NM. Assessment and management of older patients with transthyretin amyloidosis cardiomyopathy: geriatric cardiology, frailty assessment and beyond. Front Cardiovasc Med, 2022, 9:863179. https:\/\/doi.org\/10.3389\/fcvm.2022.863179","DOI":"10.3389\/fcvm.2022.863179"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"[20] Yilmaz A, Bauersachs J, Bengel F, B\u00fcchel R, Kindermann I, Klingel K, Knebel F, Meder B, Morbach C, Nagel E, Schulze-Bahr E, Aus dem Siepen F, Frey N. Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). Clin Res Cardiol, 2021, 110(4):479-506. https:\/\/doi.org\/10.1007\/s00392-020-01799-3","DOI":"10.1007\/s00392-020-01799-3"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"[21] Palma JA, Gonzalez-Duarte A, Kaufmann H. Orthostatic hypotension in hereditary transthyretin amyloidosis: epidemiology, diagnosis and management. Clin Auton Res, 2019, 29(Suppl 1):33-44. https:\/\/doi.org\/10.1007\/s10286-019-00623-x","DOI":"10.1007\/s10286-019-00623-x"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"[22] Assaf A, Mekhael M, Noujaim C, Chouman N, Younes H, Kreidieh O, Marrouche N, Donnellan E. Conduction system disease in cardiac amyloidosis. Trends Cardiovasc Med, 2024, 34(4):250-253. https:\/\/doi.org\/10.1016\/j.tcm.2023.02.004","DOI":"10.1016\/j.tcm.2023.02.004"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"[23] Khanna S, Lo P, Cho K, Subbiah R. Ventricular arrhythmias in cardiac amyloidosis: a review of current literature. Clin Med Insights Cardiol, 2020, 14:1179546820963055. https:\/\/doi.org\/10.1177\/1179546820963055","DOI":"10.1177\/1179546820963055"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"[24] Damy T, Maurer MS, Rapezzi C, Plant\u00e9-Bordeneuve V, Karayal ON, Mundayat R, Suhr OB, Kristen AV. Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy. Open Heart, 2016, 3(1):e000289. https:\/\/doi.org\/10.1136\/openhrt-2015-000289","DOI":"10.1136\/openhrt-2015-000289"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"[25] Cheng Z, Zhu K, Tian Z, Zhao D, Cui Q, Fang Q. The findings of electrocardiography in patients with cardiac amyloidosis. Ann Noninvasive Electrocardiol, 2013, 18(2):157-162. https:\/\/doi.org\/10.1111\/anec.12018","DOI":"10.1111\/anec.12018"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"[26] Martinez-Naharro A, Baksi AJ, Hawkins PN, Fontana M. Diagnostic imaging of cardiac amyloidosis. Nat Rev Cardiol, 2020, 17(7):413-426. https:\/\/doi.org\/10.1038\/s41569-020-0334-7","DOI":"10.1038\/s41569-020-0334-7"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"[27] Fontana M, Chung R, Hawkins PN, Moon JC. Cardiovascular magnetic resonance for amyloidosis. Heart Fail Rev, 2015, 20(2):133-144. https:\/\/doi.org\/10.1007\/s10741-014-9470-7","DOI":"10.1007\/s10741-014-9470-7"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"[28] Wan K, Sun J, Han Y, Luo Y, Liu H, Yang D, Cheng W, Zhang Q, Zeng Z, Chen Y. Right ventricular involvement evaluated by cardiac magnetic resonance imaging predicts mortality in patients with light chain amyloidosis. Heart Vessels, 2018, 33(2):170-179. https:\/\/doi.org\/10.1007\/s00380-017-1043-y","DOI":"10.1007\/s00380-017-1043-y"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"[29] Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM, Maestrini V, Barcella W, Rosmini S, Bulluck H, Sayed RH, Patel K, Mamhood S, Bucciarelli-Ducci C, Whelan CJ, Herrey AS, Lachmann HJ, Wechalekar AD, Manisty CH, Schelbert EB, Kellman P, Gillmore JD, Hawkins PN, Moon JC. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation, 2015, 132(16):1570-1579. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.016567","DOI":"10.1161\/CIRCULATIONAHA.115.016567"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"[30] Baggiano A, Boldrini M, Martinez-Naharro A, Kotecha T, Petrie A, Rezk T, Gritti M, Quarta C, Knight DS, Wechalekar AD, Lachmann HJ, Perlini S, Pontone G, Moon JC, Kellman P, Gillmore JD, Hawkins PN, Fontana M. Noncontrast magnetic resonance for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging, 2020, 13(1 Pt 1):69-80. https:\/\/doi.org\/10.1016\/j.jcmg.2019.03.026","DOI":"10.1016\/j.jcmg.2019.03.026"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"[31] Dorbala S, Cuddy S, Falk RH. How to image cardiac amyloidosis: a practical approach. JACC Cardiovasc Imaging, 2020, 13(6):1368-1383. https:\/\/doi.org\/10.1016\/j.jcmg.2019.07.015","DOI":"10.1016\/j.jcmg.2019.07.015"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"[32] Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AW, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation, 2016, 133(24):2404-2412. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.021612","DOI":"10.1161\/CIRCULATIONAHA.116.021612"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"[33] Saro R, Pavan D, Porcari A, Sinagra G, Mojoli M. Lights and shadows of clinical applications of cardiac scintigraphy with bone tracers in suspected amyloidosis. J Clin Med, 2023, 12(24):7605. https:\/\/doi.org\/10.3390\/jcm12247605","DOI":"10.3390\/jcm12247605"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"[34] Ahluwalia N, Roshankar G, Draycott L, Jimenez-Zepeda V, Fine N, Chan D, Han D, Miller RJH. Diagnostic accuracy of bone scintigraphy imaging for transthyretin cardiac amyloidosis: systematic review and meta-analysis. J Nucl Cardiol, 2023, 30(6):2464-2476. https:\/\/doi.org\/10.1007\/s12350-023-03297-1","DOI":"10.1007\/s12350-023-03297-1"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"[35] Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, Leone O, Farsad M, Ciliberti P, Bacchi-Reggiani L, Fallani F, Branzi A, Rapezzi C. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-Diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol, 2005, 46(6):1076-1084. https:\/\/doi.org\/10.1016\/j.jacc.2005.05.073","DOI":"10.1016\/j.jacc.2005.05.073"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"[36] Kitaoka H, Izumi C, Izumiya Y, Inomata T, Ueda M, Kubo T, Koyama J, Sano M, Sekijima Y, Tahara N, Tsukada N, Tsujita K, Tsutsui H, Tomita T, Amano M, Endo J, Okada A, Oda S, Takashio S, Baba Y, Misumi Y, Yazaki M, Anzai T, Ando Y, Isobe M, Kimura T, Fukuda K; Japanese Circulation Society Joint Working Group. JCS 2020 Guideline on diagnosis and treatment of cardiac amyloidosis. Circ J, 2020, 84(9):1610-1671. https:\/\/doi.org\/10.1253\/circj.CJ-20-0110","DOI":"10.1253\/circj.CJ-20-0110"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"[37] Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, Fontana M, Gheysens O, Gillmore JD, Glaudemans AWJM, Hanna MA, Hazenberg BPC, Kristen AV, Kwong RY, Maurer MS, Merlini G, Miller EJ, Moon JC, Murthy VL, Quarta CC, Rapezzi C, Ruberg FL, Shah SJ, Slart RHJA, Verberne HJ, Bourque JM. ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI Expert Consensus Recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2 - diagnostic criteria and appropriate utilization. J Nucl Cardiol, 2020, 27(2):659-673. https:\/\/doi.org\/10.1007\/s12350-019-01761-5","DOI":"10.1007\/s12350-019-01761-5"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"[38] Writing Committee; Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO, Dember LM, Frantz JG, Hershberger RE, Maurer MS, Nativi-Nicolau J, Sanchorawala V, Sheikh FH. 2023 ACC Expert Consensus Decision Pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol, 2023, 81(11):1076-1126. https:\/\/doi.org\/10.1016\/j.jacc.2022.11.022","DOI":"10.1016\/j.jacc.2022.11.022"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"[39] Hanna M, Ruberg FL, Maurer MS, Dispenzieri A, Dorbala S, Falk RH, Hoffman J, Jaber W, Soman P, Witteles RM, Grogan M. Cardiac scintigraphy with technetium-99m-labeled bone-seeking tracers for suspected amyloidosis: JACC review topic of the week. J Am Coll Cardiol, 2020, 75(22):2851-2862. https:\/\/doi.org\/10.1016\/j.jacc.2020.04.022","DOI":"10.1016\/j.jacc.2020.04.022"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"[40] Witteles RM, Liedtke M. Avoiding catastrophe: understanding free light chain testing in the evaluation of ATTR amyloidosis. Circ Heart Fail, 2021, 14(4):e008225. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.120.008225","DOI":"10.1161\/CIRCHEARTFAILURE.120.008225"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"[41] Maestro-Benedicto A, Vela P, de Frutos F, Mora N, Pomares A, Gonzalez-Vioque E, Brice\u00f1o A, Cabrera E, Cobo-Marcos M, Dominguez F, Gonzalez-Lopez E, Segovia J, Lara-Pezzi E, Garcia-Pavia P. Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy. Eur J Heart Fail, 2022, 24(12):2367-2373. https:\/\/doi.org\/10.1002\/ejhf.2658","DOI":"10.1002\/ejhf.2658"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"[42] Cantone A, Sanguettoli F, Dal Passo B, Serenelli M, Rapezzi C. The treatment of amyloidosis is being refined. Eur Heart J Suppl, 2022, 24(Suppl I):I131-I138. https:\/\/doi.org\/10.1093\/eurheartjsupp\/suac104","DOI":"10.1093\/eurheartjsupp\/suac104"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"[43] Adam RD, Coriu D, Jercan A, B\u0103deli\u0163\u0103 S, Popescu BA, Damy T, Jurcu\u0163 R. Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature. ESC Heart Fail, 2021, 8(4):2380-2396. https:\/\/doi.org\/10.1002\/ehf2.13443","DOI":"10.1002\/ehf2.13443"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"[44] Patel AGM, Li P, Badrish N, Kesari A, Shah KB. Transthyretin cardiac amyloidosis: current and emerging therapies. Curr Cardiol Rep, 2025, 27(1):33. https:\/\/doi.org\/10.1007\/s11886-024-02172-w","DOI":"10.1007\/s11886-024-02172-w"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"[45] Ibrahim M, Saint Croix GR, Lacy S, Fattouh M, Barillas-Lara MI, Behrooz L, Mechanic O. The use of Diflunisal for transthyretin cardiac amyloidosis: a review. Heart Fail Rev, 2022, 27(2):517-524. https:\/\/doi.org\/10.1007\/s10741-021-10143-4","DOI":"10.1007\/s10741-021-10143-4"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"[46] Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C; ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med, 2018, 379(11):1007-1016. https:\/\/doi.org\/10.1056\/NEJMoa1805689","DOI":"10.1056\/NEJMoa1805689"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"[47] Shah SJ, Fine N, Garcia-Pavia P, Klein AL, Fernandes F, Weissman NJ, Maurer MS, Boman K, Gundapaneni B, Sultan MB, Elliott P. Effect of Tafamidis on cardiac function in patients with transthyretin amyloid cardiomyopathy: a post hoc analysis of the ATTR-ACT randomized clinical trial. JAMA Cardiol, 2024, 9(1):25-34. https:\/\/doi.org\/10.1001\/jamacardio.2023.4147","DOI":"10.1001\/jamacardio.2023.4147"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"[48] Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pav\u00eda P, Gibbs S, Grogan M, Hanna M, Hoffman J, Masri A, Maurer MS, Nativi-Nicolau J, Obici L, Poulsen SH, Rockhold F, Shah KB, Soman P, Garg J, Chiswell K, Xu H, Cao X, Lystig T, Sinha U, Fox JC; ATTRibute-CM Investigators. Efficacy and safety of Acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med, 2024, 390(2):132-142. https:\/\/doi.org\/10.1056\/NEJMoa2305434","DOI":"10.1056\/NEJMoa2305434"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"[49] Ioannou A, Massa P, Patel RK, Razvi Y, Porcari A, Rauf MU, Jiang A, Cabras G, Filisetti S, Bolhuis RE, Bandera F, Venneri L, Martinez-Naharro A, Law S, Kotecha T, Virsinskaite R, Knight DS, Emdin M, Petrie A, Lachmann H, Wechelakar A, Petrie M, Hughes A, Freemantle N, Hawkins PN, Whelan C, McMurray JJV, Gillmore JD, Fontana M. Conventional heart failure therapy in cardiac ATTR amyloidosis. Eur Heart J, 2023, 44(31):2893-2907. https:\/\/doi.org\/10.1093\/eurheartj\/ehad347","DOI":"10.1093\/eurheartj\/ehad347"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"[50] Maurer MS, Kale P, Fontana M, Berk JL, Grogan M, Gustafsson F, Hung RR, Gottlieb RL, Damy T, Gonz\u00e1lez-Duarte A, Sarswat N, Sekijima Y, Tahara N, Taylor MS, Kubanek M, Donal E, Palecek T, Tsujita K, Tang WHW, Yu WC, Obici L, Sim\u00f5es M, Fernandes F, Poulsen SH, Diemberger I, Perfetto F, Solomon SD, Di Carli M, Badri P, White MT, Chen J, Yureneva E, Sweetser MT, Jay PY, Garg PP, Vest J, Gillmore JD; APOLLO-B Trial Investigators. Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med, 2023, 389(17):1553-1565. https:\/\/doi.org\/10.1056\/NEJMoa2300757","DOI":"10.1056\/NEJMoa2300757"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"[51] Martinez-Naharro A, Hawkins PN, Fontana M. Cardiac amyloidosis. Clin Med (Lond), 2018, 18(Suppl 2):s30-s35. https:\/\/doi.org\/10.7861\/clinmedicine.18-2-s30","DOI":"10.7861\/clinmedicine.18-2-s30"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"[52] Takanashi T, Matsuda M, Yazaki M, Yamazaki H, Nawata M, Katagiri Y, Ikeda S. Synovial deposition of wild-type transthyretin-derived amyloid in knee joint osteoarthritis patients. Amyloid, 2013, 20(3):151-155. https:\/\/doi.org\/10.3109\/13506129.2013.803190","DOI":"10.3109\/13506129.2013.803190"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"[53] Yanagisawa A, Ueda M, Sueyoshi T, Nakamura E, Tasaki M, Suenaga G, Motokawa H, Toyoshima R, Kinoshita Y, Misumi Y, Yamashita T, Sakaguchi M, Westermark P, Mizuta H, Ando Y. Knee osteoarthritis associated with different kinds of amyloid deposits and the impact of aging on type of amyloid. Amyloid, 2016, 23(1):26-32. https:\/\/doi.org\/10.3109\/13506129.2015.1115758","DOI":"10.3109\/13506129.2015.1115758"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"[54] Matsuzaki T, Akasaki Y, Olmer M, Alvarez-Garcia O, Reixach N, Buxbaum JN, Lotz MK. Transthyretin deposition promotes progression of osteoarthritis. Aging Cell, 2017, 16(6):1313-1322. https:\/\/doi.org\/10.1111\/acel.12665","DOI":"10.1111\/acel.12665"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"[55] Sekijima Y, Yazaki M, Ueda M, Koike H, Yamada M, Ando Y. First nationwide survey on systemic wild-type ATTR amyloidosis in Japan. Amyloid, 2018, 25(1):8-10. https:\/\/doi.org\/10.1080\/13506129.2017.1409706","DOI":"10.1080\/13506129.2017.1409706"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"[56] Coelho T, Maurer MS, Suhr OB. THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical mani-festations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin, 2013, 29(1):63-76. https:\/\/doi.org\/10.1185\/03007995.2012.754348","DOI":"10.1185\/03007995.2012.754348"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"[57] Tsukada T, Tanaka M, Miyazaki Y, Nishiura Y, Yamashita T, Kishikawa M. A case of unilateral shoulder joint hydrarthrosis with wild type amyloidogenic transthyretin amyloidosis. Mod Rheumatol Case Rep, 2020, 4(2):312-317. https:\/\/doi.org\/10.1080\/24725625.2020.1751380","DOI":"10.1080\/24725625.2020.1751380"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"[58] Mart\u00ednez-Valle F, Casasnovas-Pons C, Romero-Acebal M, Gal\u00e1n-D\u00e1vila L. Evaluation of autonomic dysfunction in hereditary transthyretin amyloidosis [Evaluaci\u00f3n de la disfunci\u00f3n auton\u00f3mica en la amiloidosis hereditaria por transtiretina]. Neurolog\u00eda, 2024, Dec 6. https:\/\/doi.org\/10.1016\/j.nrl.2023.04.010","DOI":"10.1016\/j.nrl.2023.04.010"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"[59] Verrillo F, Palmiero G, Monda E, Dongiglio F, Diana G, Sinagra G, Emdin M, Limongelli G. The role of echocardiography for the clinical diagnosis, risk stratification, and management of cardiac amyloidosis. Heart Fail Clin, 2024, 20(3):271-282. https:\/\/doi.org\/10.1016\/j.hfc.2024.03.008","DOI":"10.1016\/j.hfc.2024.03.008"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"[60] Moraru L, Mirea O, Toader D, Berceanu M, Soldea S, Munteanu A, Donoiu I, Raicea V. Lower limit of normality of segmental multilayer longitudinal strain in healthy adult subjects. J Cardiovasc Dev Dis, 2024, 11(4):102. https:\/\/doi.org\/10.3390\/jcdd11040102","DOI":"10.3390\/jcdd11040102"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"[61] Aimo A, Camerini L, Fabiani I, Morfino P, Panichella G, Barison A, Pucci A, Castiglione V, Vergaro G, Sinagra G, Emdin M. Valvular heart disease in patients with cardiac amyloidosis. Heart Fail Rev, 2024, 29(1):65-77. https:\/\/doi.org\/10.1007\/s10741-023-10350-1","DOI":"10.1007\/s10741-023-10350-1"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"[62] Don\u00e0 C, Nitsche C, Koschutnik M, Heitzinger G, Mascherbauer K, Kammerlander AA, Dannenberg V, Halavina K, Rettl R, Duca F, Traub-Weidinger T, Puchinger J, Gunacker PC, Lamm G, Vock P, Lileg B, Philipp V, Staudenherz A, Calabretta R, Hacker M, Agis H, Bartko P, Hengstenberg C, Fontana M, Goliasch G, Mascherbauer J. Unveiling cardiac amyloidosis, its characteristics, and outcomes among patients with MR undergoing transcatheter edge-to-edge MV repair. JACC Cardiovasc Interv, 2022, 15(17):1748-1758. https:\/\/doi.org\/10.1016\/j.jcin.2022.06.009","DOI":"10.1016\/j.jcin.2022.06.009"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"[63] Duca F, Kronberger C, Willixhofer R, Bartko PE, Bergler-Klein J, Nitsche C. Cardiac amyloidosis and valvular heart disease. J Clin Med, 2023, 13(1):221. https:\/\/doi.org\/10.3390\/jcm13010221","DOI":"10.3390\/jcm13010221"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"[64] Chacko L, Karia N, Venneri L, Bandera F, Passo BD, Buonamici L, Lazari J, Ioannou A, Porcari A, Patel R, Razvi Y, Brown J, Knight D, Martinez-Naharro A, Whelan C, Quarta CC, Manisty C, Moon J, Rowczenio D, Gilbertson JA, Lachmann H, Wechelakar A, Petrie A, Moody WE, Steeds RP, Potena L, Riefolo M, Leone O, Rapezzi C, Hawkins PN, Gillmore JD, Fontana M. Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis. Eur J Heart Fail, 2022, 24(9):1700-1712. https:\/\/doi.org\/10.1002\/ejhf.2606","DOI":"10.1002\/ejhf.2606"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"[65] Xu B, Godoy Rivas C, Rodriguez ER, Tan C, Gillinov AM, Harb S, Jellis C, Griffin B. Unrecognized cardiac amyloidosis at the time of mitral valve surgery: incidence and outcomes. Cardiology, 2019, 142(4):253-258. https:\/\/doi.org\/10.1159\/000499933","DOI":"10.1159\/000499933"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"[66] Nishi H, Mitsuno M, Ryomoto M, Miyamoto Y. Severe mitral regurgitation due to cardiac amyloidosis - a rare reason for ruptured chordae. Interact Cardiovasc Thorac Surg, 2008, 7(6):1199-1200. https:\/\/doi.org\/10.1510\/icvts.2008.187179","DOI":"10.1510\/icvts.2008.187179"},{"key":"ref66","unstructured":"[67] Nemes A, F\u00f6lde\u00e1k D, Korm\u00e1nyos \u00c1, Domsik P, Kalapos A, Borb\u00e9nyi Z, Forster T. Cardiac amyloidosis associated with enlargement and functional impairment of the mitral annulus: insights from the three-dimensional speckle tracking echocardiographic MAGYAR path study. J Heart Valve Dis, 2017, 26(3):304-308."},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"[68] El Sabbagh A, Reddy YNV, Nishimura RA. Mitral valve regurgitation in the contemporary era: insights into diagnosis, management, and future directions. JACC Cardiovasc Imaging, 2018, 11(4):628-643. https:\/\/doi.org\/10.1016\/j.jcmg.2018.01.009","DOI":"10.1016\/j.jcmg.2018.01.009"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"[69] Volz MJ, Pleger ST, Weber A, Geis NA, Hamed S, Mereles D, Hegenbart U, Katus HA, Frey N, Raake PW, Kreusser MM. Initial experience with percutaneous mitral valve repair in patients with cardiac amyloidosis. Eur J Clin Invest, 2021, 51(6):e13473. https:\/\/doi.org\/10.1111\/eci.13473","DOI":"10.1111\/eci.13473"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"[70] Thakker RA, Elbadawi A, Albaeni A, Hasan SM, Suthar KH, Modi SA, Berbarie RF, Khalife W, Chatila KF. Percutaneous mitral valve repair in cardiac amyloidosis and severe mitral regurgitation. Curr Probl Cardiol, 2022, 47(9):100881. https:\/\/doi.org\/10.1016\/j.cpcardiol.2021.100881","DOI":"10.1016\/j.cpcardiol.2021.100881"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"[71] Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac amyloidosis. Cardiovasc Res, 2023, 118(18):3517-3535. https:\/\/doi.org\/10.1093\/cvr\/cvac119","DOI":"10.1093\/cvr\/cvac119"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"[72] Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Zumbo G, Knight DS, Kotecha T, Francis R, Hutt DF, Rezk T, Rosmini S, Quarta CC, Whelan CJ, Kellman P, Gillmore JD, Moon JC, Hawkins PN, Fontana M. Magnetic resonance in transthyretin cardiac amyloidosis. J Am Coll Cardiol, 2017, 70(4):466-477. https:\/\/doi.org\/10.1016\/j.jacc.2017.05.053","DOI":"10.1016\/j.jacc.2017.05.053"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"[73] Wu D, Chen W. Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy. Heart Fail Rev, 2024, 29(2):511-521. https:\/\/doi.org\/10.1007\/s10741-023-10380-9","DOI":"10.1007\/s10741-023-10380-9"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"[74] Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, Nair AP, Nativi-Nicolau J, Ruberg FL; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation, 2020, 142(1):e7-e22. https:\/\/doi.org\/10.1161\/CIR.0000000000000792\"","DOI":"10.1161\/CIR.0000000000000792"}],"container-title":["Romanian Journal of Morphology and Embryology"],"original-title":[],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T12:41:21Z","timestamp":1756730481000},"score":1,"resource":{"primary":{"URL":"https:\/\/rjme.ro\/archive\/66\/2\/2\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":74,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,8,20]]},"published-print":{"date-parts":[[2025,8,27]]}},"URL":"https:\/\/doi.org\/10.47162\/rjme.66.2.02","relation":{},"ISSN":["1220-0522","2066-8279"],"issn-type":[{"value":"1220-0522","type":"print"},{"value":"2066-8279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]}}}